Given the numerous randomized clinical trials (RCTs) of antidopaminergic agents for schizophrenia, meta-analyses can help compare their efficacy and safety/tolerability. Because many medications have never been directly compared, network meta-analyses (NMAs) using direct and indirect effect size estimates via common comparators have been introduced. Because “transitivity” (eg, similar populations, treatment, and measurement approaches) is required, changes in patient, illness, treatment, trial design/conduct characteristics, and increasing placebo effects in schizophrenia trials1 challenge the underlying assumptions of NMAs.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Correll CU, Kane JM. Ranking Antipsychotics for Efficacy and Safety in Schizophrenia. JAMA Psychiatry. Published online November 06, 2019. doi:https://doi.org/10.1001/jamapsychiatry.2019.3377
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: